MorphoSys AG (WBO:MOR) Interest Expense : €-132.3 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MorphoSys AG's interest expense for the three months ended in Dec. 2023 was € -8.7 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-132.3 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MorphoSys AG's Operating Income for the three months ended in Dec. 2023 was € -81.4 Mil. MorphoSys AG's Interest Expense for the three months ended in Dec. 2023 was € -8.7 Mil. MorphoSys AG did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MorphoSys AG Interest Expense Historical Data

The historical data trend for MorphoSys AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Interest Expense Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.02

-19.98

-65.82

-116.52

-109.86

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															298.88	-28.26	-28.32	-67.10	-8.66

MorphoSys AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-132.3 Mil.

MorphoSys AG (WBO:MOR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

MorphoSys AG's Interest Expense for the three months ended in Dec. 2023 was €-8.7 Mil. Its Operating Income for the three months ended in Dec. 2023 was €-81.4 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €621.9 Mil.

MorphoSys AG's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

MorphoSys AG did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.